Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2018’, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH)

- The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Heterozygous familial hypercholesterolemia (heFH) therapeutics and enlists all their major and minor projects

- The report assesses Heterozygous familial hypercholesterolemia (heFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heterozygous familial hypercholesterolemia (heFH) - Overview

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Heterozygous familial hypercholesterolemia (heFH) - Overview

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development

Daewoong Co Ltd

Esperion Therapeutics Inc

Gemphire Therapeutics Inc

Innovent Biologics Inc

Madrigal Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

The Medicines Company

Heterozygous familial hypercholesterolemia (heFH) - Drug Profiles

(bempedoic acid + ezetimibe) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcabene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBI-306 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inclisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MGL-3745 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects

Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products

Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones

Featured News & Press Releases

Aug 27, 2018: Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study

Feb 20, 2018: The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule

Feb 08, 2018: Madrigal's MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia

Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit

Sep 19, 2017: Madrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

May 11, 2017: Madrigal Pharmaceuticals Provides Update on lead compound MGL-3196

Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection

Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Feb 23, 2017: Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia

Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection

Nov 28, 2016: Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia

Nov 11, 2016: Regeneron and Sanofi to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016

Aug 29, 2016: Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016

May 24, 2016: New Cholesterol Treatment Now Available for Canadians

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products ...

List of Tables

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Daewoong Co Ltd, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Esperion Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Gemphire Therapeutics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Innovent Biologics Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Pipeline by The Medicines Company, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H2 2018

Heterozygous familial hypercholesterolemia (heFH) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018 7

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H2 2018 7

Number of Products under Development by Companies, H2 2018 8

Number of Products by Targets, H2 2018 11

Number of Products by Stage and Targets, H2 2018 11

Number of Products by Mechanism of Actions, H2 2018 13

Number of Products by Stage and Mechanism of Actions, H2 2018 13

Number of Products by Routes of Administration, H2 2018 15

Number of Products by Stage and Routes of Administration, H2 2018 15

Number of Products by Molecule Types, H2 2018 17

Number of Products by Stage and Molecule Types, H2 2018 17

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports